Cancer is a serious problem affecting the health of human and isone of the leading cause of mortality worldwide. A normal cell undergoes regulated cell division, differentiation and apoptosis (programmed cell death). When normal cell has lost the usual control over their division, differentiation and apoptosis they become tumor cells. Cancer arises mainly from mutations in somatic cells. Maintenance of genomic integrity is a pre-requisite for a safe and long lasting life. For this purpose, cell has quality control points, referred as checkpoints. The different mechanisms and multiple researchers involved in the field necessiatean understanding of the molecular mechanism to classify tumor and to assess the risk and treatment of disease. Certain therapeutic strategies exist and many more need to be explored. Different experimental therapies are currently in clinical trials and are raising hopes that a new class of anti-cancer drug may soon be available.
Cite this article:
Farha Fatma, Anil Kumar. The Cell Cycle, Cyclins, Checkpoints and Cancer. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(2):175-3. doi: 10.52711/2231-5659.2021-11-2-14
Farha Fatma, Anil Kumar. The Cell Cycle, Cyclins, Checkpoints and Cancer. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(2):175-3. doi: 10.52711/2231-5659.2021-11-2-14 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2021-11-2-14
1. Bartek J and Lukas J (2001) Pathways governing G1/S transition and their response to DNA damage. FEBS Letters 490: 117–122.
2. Bertoni, F. et al. (1999) CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 26, 176–180
3. Bell, D.W. et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286, 2528–2531
4. Cahill, D.P. et al. (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392, 300–303
5. Evans T, Rosenthal ET, Youngblom J et al. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 1983;33: 389-396.
6. Ewen ME. The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev 1994;13: 45-66.
7. Gerdes B, Ramaswamy A, Ziegler A et al. p16INK4a is a prognosticmarker in resected ductal pancreatic cancer: an analysisof p16INK4a, p53, MDM2, and Rb. Ann Surg 2002;235: 51-59.
8. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266: 1821-1828.
9. Hartwell LH and Weinert TA (1989) Checkpoints: controls that ensurethe order of cell cycle events. Science 246: 629–634.
10. Hartwell LH, Culotti J, Pringle JRand Reid BJ (1974) Genetic control ofthe cell division cycle in yeast. Science 183: 46–51.
11. HoytMA, Totis Land Roberts BT (1991) S. cerevisiae genes required forcell cycle arrest in response to loss of microtubule function. Cell 66:507–517.
12. Howes, K. A., Ransom, N., Papermaster, D. S., Lasudry, J. G. H., Albert, D. M. &Windle, J. J. (1994) Genes Dev. 8, 1300–1310.
13. Jinno S, Hung SC, Okayama H. Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4. Oncogene 1999;18: 565-571.
14. Khanna, K.K. (2000) Cancer risk and the ATM gene: a continuing debate. J. Natl. Cancer Inst. 92, 795–802
15. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E. & Jacks, T. (1994) Science266, 807–810.
16. Lee, H. et al. (1999) Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol. Cell 4, 1–10
17. Li X, Hui AM, Shi YZ et al. Reduced p21(WAF1/CIP1) expression is an early event in gallbladder carcinogenesis and is of prognostic significance for patients with carcinomas of the gallbladder. Hum Pathol 2001;32: 771-777.
18. Morgan DO. Principles of CDK regulation. Nature. 1995 Mar 9;374(6518):131-4
19. Morgan DO. Principles of CDK regulation. Nature 1995;374: 131-134.
20. Michalides R. Prognosis for G1 cell-cycle regulators: useful for predicting course of disease and for assessment of therapy in cancer. J Pathol 1999;18 8:341-343.
21. Morgenbesser, S. D., Williams, B. O., Jacks, T. &DePinho, R. A. (1994) Nature (London) 371, 72–74.
22. Muraoka, R.S. et al. (2002) ErbB2/Neu-induced, cyclin D1-dependent transformation Is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 22, 2204–2219
23. Matsuoka, S. et al. (2001) Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res. 61, 5362–5365
24. Owa T, Yoshino H, Yoshimatsu K et al. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2001;8: 1487-1503.
25. Oya, M. and Schulz, W.A. (2000) Decreased expression of p57(KIP2) mRNA in human bladder cancer. Br. J. Cancer 83, 626–631
26. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 1999 Apr 16;287(5):821-8
27. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica- Worms H. Mitotic and G2 checkpoint control: regulation of 14- 3-3 protein binding by phosphorylation of Cdc25C on serine- 216. Science. 1997 Sep 5;277(5331):1501-5.
28. Porter, P.L. et al. (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3, 222–225
29. Pinyol M, Hernandez L, Cazorla M, Balbín M, Jares P, Fernandez PL, Montserrat E, Cardesa A, Lopez-Otín C, Campo E. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 1997 Jan 1;89(1):272-80
30. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999 Jun 15;13(12):1501-12
31. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T. & Van Dyke, T. (1994) Cell 78, 703–711.
32. Senderowicz AM. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 2000;19: 6600-6666.
33. Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001;15: 1-9.
34. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92: 376-387.
35. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13: 1501-1512.
36. Solomon MJ, Kaldis P. Regulation of CDKs by phosphorylation. Results Probl Cell Differ 1998;22: 79-109.
37. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398: 422-426.
38. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411: 1017-1021.
39. Yang J, Bardes ES, Moore JD, Brennan J, Powers MA, Kornbluth S. Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. Genes Dev. 1998 Jul 15;12(14):2131-43